Cargando…

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells

Treating BRAF inhibitor-resistant melanoma is an important therapeutic goal. Thus, it is important to identify and target mechanisms of resistance to improve therapy. The YAP1 and TAZ proteins of the Hippo signaling pathway are important drivers of cancer cell survival, and are BRAF inhibitor resist...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fisher, Matthew L., Grun, Daniel, Adhikary, Gautam, Xu, Wen, Eckert, Richard L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746380/ https://www.ncbi.nlm.nih.gov/pubmed/29299145 http://dx.doi.org/10.18632/oncotarget.22628

Ejemplares similares

Sulforaphane reduces YAP/∆Np63α signaling to reduce cancer stem cell survival and tumor formation
por: Fisher, Matthew L., et al.
Publicado: (2017)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

USP22 promotes melanoma and BRAF inhibitor resistance via YAP stabilization
por: Wei, Ying, et al.
Publicado: (2021)

Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma
por: Chan, Xian Yang, et al.
Publicado: (2017)

Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors
por: Azimi, Alireza, et al.
Publicado: (2018)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Chk1 inhibition as a novel therapeutic strategy in melanoma
por: Hwang, Bor-Jang, et al.
Publicado: (2018)

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma
por: Lassen, Amanda, et al.
Publicado: (2014)

Resistance to BRAF inhibitors induces glutamine dependency in melanoma cells
por: Baenke, Franziska, et al.
Publicado: (2015)

Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors
por: Mulcahy Levy, Jean M, et al.
Publicado: (2017)

Type II transglutaminase stimulates epidermal cancer stem cell epithelial-mesenchymal transition
por: Fisher, Matthew L., et al.
Publicado: (2015)

Potential Therapeutic Strategies to Overcome Acquired Resistance to BRAF or MEK Inhibitors in BRAF Mutant Cancers
por: Corcoran, Ryan B., et al.
Publicado: (2011)

Transglutaminase is a mesothelioma cancer stem cell survival protein that is required for tumor formation
por: Adhikary, Gautam, et al.
Publicado: (2018)

BRAF inhibitors: resistance and the promise of combination treatments for melanoma
por: Griffin, Merope, et al.
Publicado: (2017)

Overcoming resistance to BRAF(V600E) inhibition in melanoma by deciphering and targeting personalized protein network alterations
por: Vasudevan, S., et al.
Publicado: (2021)

BRAF in Melanoma: Pathogenesis, Diagnosis, Inhibition, and Resistance
por: Sullivan, Ryan J., et al.
Publicado: (2011)

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicing
por: Pupo, Gulietta M., et al.
Publicado: (2017)

BRAF associated autophagy exploitation: BRAF and autophagy inhibitors synergise to efficiently overcome resistance of BRAF mutant colorectal cancer cells
por: Goulielmaki, Maria, et al.
Publicado: (2016)

Adaptive Responses as Mechanisms of Resistance to BRAF Inhibitors in Melanoma
por: Saei, Azad, et al.
Publicado: (2019)

Clinical Implications of Acquired BRAF Inhibitors Resistance in Melanoma
por: Savoia, Paola, et al.
Publicado: (2020)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

Grp94-specific monoclonal antibody to counteract BRAF inhibitor resistance in BRAF(V600E) melanoma
por: Sabbatino, F, et al.
Publicado: (2015)

Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer
por: Yun, Mi Ran, et al.
Publicado: (2019)

SEMA6A/RhoA/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF/MEK inhibition in BRAF-mutant melanoma
por: Loria, Rossella, et al.
Publicado: (2022)

Resistance surveillance in a BRAF mutant melanoma patient on long-term BRAF-inhibitor treatment
por: Mak, Gabriel, et al.
Publicado: (2014)

Upregulation of MicroRNA-1246 Is Associated with BRAF Inhibitor Resistance in Melanoma Cells with Mutant BRAF
por: Kim, Jae-Hyeon, et al.
Publicado: (2017)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

BRAF inhibitor resistance enhances vulnerability to arginine deprivation in melanoma
por: Li, Ying-Ying, et al.
Publicado: (2016)

Gene Expression Signature of BRAF Inhibitor Resistant Melanoma Spheroids
por: Koroknai, Viktoria, et al.
Publicado: (2020)

BRAF Inhibitor Resistance in Melanoma: Mechanisms and Alternative Therapeutic Strategies
por: Zhong, Jingqin, et al.
Publicado: (2022)

Targeting of the Lipid Metabolism Impairs Resistance to BRAF Kinase Inhibitor in Melanoma
por: Vergani, Elisabetta, et al.
Publicado: (2022)

Pericentrosomal localization of the TIG3 tumor suppressor requires an N-terminal hydrophilic region motif
por: Scharadin, Tiffany M., et al.
Publicado: (2013)

HI-511 overcomes melanoma drug resistance via targeting AURKB and BRAF V600E
por: Chang, Xiaoyu, et al.
Publicado: (2020)

PERK mediates resistance to BRAF inhibition in melanoma with impaired PTEN
por: Qin, Yifei, et al.
Publicado: (2021)

Strategies for Overcoming Resistance in Tumours Harboring BRAF Mutations
por: Obaid, Nourah Mohammad, et al.
Publicado: (2017)

Kisspeptin-mediated improvement of sensitivity to BRAF inhibitors in vemurafenib-resistant melanoma cells
por: Guzzetti, Carlotta, et al.
Publicado: (2023)

BET and BRAF inhibitors act synergistically against BRAF‐mutant melanoma
por: Paoluzzi, Luca, et al.
Publicado: (2016)

Attenuation of YAP1 can potentially target cancer stem cells to overcome drug resistance
por: Harada, Kazuto, et al.
Publicado: (2018)

An allosteric pan-TEAD inhibitor blocks oncogenic YAP/TAZ signaling and overcomes KRAS G12C inhibitor resistance
por: Hagenbeek, Thijs J., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_26b9lepqnr34el2ti2qeuq2bsd